Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (348,283)	$ (258,869)	$ (15,493,165)	$ (623,035)	$ (607,152)	$ (16,116,200)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation					20,004	0
Amortization					99,055	212,406
Amortization of debt discount						75,755
Lease expense						10,749
Stock-based compensation – employees			14,925,572		0	15,001,322
Stock-based compensation – non-employees						897,000
Shares issued for interest					5,030	103,350
Change in fair value of patent acquisition liability			(1,078,000)			(1,078,000)
Foreign exchange loss (gain)						55,924
Changes in operating assets and liabilities which provided (used) cash
Account Receivables					89,180	0
Operating lease liabilities					(20,880)	0
Prepaid expenses and other assets					10,762	8,075
Other receivable					20,912	89,370
Accounts payable					(44,029)	59,459
Accounts payable – related parties					(25,861)	0
Accrued interest – related and non-related parties					170,459	325,327
Accrued expenses					(138,587)	78,000
Net cash used in operating activities					(421,107)	(277,463)
Cash flows used in investing activities
Advances to CEN Biotech Ukraine LLC					0	(120,000)
Cash flows provided by financing activities
Repayment of loans payable - related parties						(50,000)
Issuance of convertible notes					70,000	408,395
Additional paid in capital					406,313	0
Issuance of convertible notes – related parties					0	48,000
Net cash provided by financing activities					476,313	406,395
Net increase in cash and cash equivalents					55,206	8,932
Cash and cash equivalents, beginning of period		$ 10,840		$ 1,908	10,840	1,908	$ 1,908
Cash and cash equivalents, end of period	$ 66,046		$ 10,840		66,046	10,840	$ 10,840	$ 1,908
Supplemental cash flows disclosures
Cash paid for interest					0	25,821
Non-cash transactions - investing and financing activities
Issuance of common stock - settlement of interest					5,030	78,893
Issuance of common stock - settlement of accrued liability					401,283	13,390
Convertible Debt [Member]
Cash flows provided by financing activities
Issuance of convertible notes					70,000
Non-cash transactions - investing and financing activities
Debt Instrument, Convertible, Beneficial Conversion Feature						111,306		$ 0
Conversion of Convertible Notes into Common Stock [Member]
Non-cash transactions - investing and financing activities
Issuance of common stock – upon conversion of convertible notes					0	4,855,861
Conversion of Related Party Convertible Notes into Common stock [Member]
Non-cash transactions - investing and financing activities
Issuance of common stock – upon conversion of convertible notes					$ 0	$ 68,000